A Phase 2 interventional study of Ruxolitinib and Regorafenib in CRC (Colorectal Cancer), sponsored by Incyte Corporation. Terminated at 86 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-13.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Colorectal Neoplasms by Incyte Corporation — 3 open to participants now, 5 under way, 1 of them phase 3. Colorectal Neoplasms · Incyte Corporation.
Among the 19 studies in Colorectal Neoplasms by Incyte Corporation, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 3 in phase 2, and was the 1st registered.
6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.
Browse Colorectal Neoplasms studies →3 of the 19 studies in Colorectal Neoplasms by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Puerto Rico
Ages 18+
Incyte Corporation · Sites in United States, Argentina, Australia and 19 more countries
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 1
First in 2014; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 396 is above the median of 76 across 4,810 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 70 across the 19 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
3 of the studies in Colorectal Neoplasms by Incyte Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06179160Incyte CorporationA Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | 2027-01-01 |
| NCT06818812Incyte CorporationA Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | 2027-03-27 |
| NCT02955940Incyte CorporationAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies in Colorectal Neoplasms by Incyte Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer.
The study consisted of an open-label, Part 1 safety run-in (consisting of 1 to 3 cohorts of 9 subjects each), to confirm the safety of the regorafenib/ruxolitinib combination in subjects with relapsed or refractory metastatic colorectal cancer (CRC). If determined to be tolerable, Part 2 was to proceed as a randomized, double-blind study evaluating ruxolitinib or placebo in combination with regorafenib in subjects with relapsed or refractory metastatic CRC previously treated with fluoropyrimidine, oxaliplatin, and/or irinotecan based chemotherapy, an anti-vascular endothelial growth factor (VEGF) therapy and if Kirsten rat sarcoma (KRAS) wild type an anti-epidermal growth factor receptor (EGFR) therapy.
Subjects in the safety run-in received open-label ruxolitinib and regorafenib; for the randomized, double-blind portion of the study all subjects received regorafenib and either ruxolitinib or placebo in a 1:1 blinded manner. Treatment for all subjects consisted of repeating 28-day cycles. Regorafenib was self-administered for the first 21 days of each cycle, and ruxolitinib/placebo was self-administered during the entire 28-day cycle. Treatment cycles continued as long as the regimen is tolerated, and the subject does not meet the discontinuation criteria. When subjects discontinued regorafenib, ruxolitinib or placebo they remained in the study and were followed for subsequent treatment regimens which were initiated and survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ruxolitinib · Drug: Regorafenib
Drug: Regorafenib · Drug: Placebo
5 mg tablets to be administered by mouth Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)
Also known as: Jakafi ®, Jakavi ®
Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
Also known as: Stivarga ®
5 mg matching placebo tablets to be administered by mouth
Overall Survival (OS)
Overall survival is defined as the time from randomization to death due to any cause. Participants without death observed at the time of the analysis will be censored at last date known to be alive. The median overall survival time was estimated using the Kaplan-Meier method. Overall survival was compared between treatment groups using log-rank test.
Time frame: Baseline until death due to any cause; up to 16 months or data cut-off 11 FEB 2016.
Progression Free Survival (PFS)
Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at least a 20% increase in the sum of the Longest Diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions, or the appearance of new lesions.
Time frame: Baseline through disease progression, or death due to any cause if sooner; up to 16 months or data cut-off 11 FEB 2016.
Overall Response Rate (ORR)
Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target and non-target lesions without new lesion; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions, non-target lesion not progressed, and no new lesion; Progressive Disease=20% increase in sum of longest diameter of target lesions, or non-target lesion progression, or identification of new lesion; Stable Disease=small changes that do not meet above criteria. ORR was defined as the proportion of participants who achieved a best response of either CR or PR. ORR=number of participants with CR or PR/number of participants randomized.
Time frame: Baseline through end of study; up to 16 months or data cut-off 11 FEB 2016.
Duration of Response
Duration of response is defined as the time from response (CR/PR) until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause.
Time frame: Baseline through end of study; up to 16 months or data cut-off 11 FEB 2016.
Percentage of Participants Achieving Disease Control
Disease control as measured by the percentage of participants whose best response was complete response (CR), partial response (PR), or stable disease (SD) per RECIST v.1.1.
Time frame: Baseline through end of study; up to 16 months or data cut-off 11 FEB 2016.
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
TEAEs were defined as any adverse event (AE) during the study that began or worsened on or after the date of first dose of investigational product.
Time frame: Baseline through approximately 30 days post treatment discontinuation;up to 16 months or data cut-off 27JAN 2016 for Substudy 1 and up to the data cut-off of 11FEB2016 for Substudy 2.
In Substudy 1, the first subject was enrolled on 29 OCT 2014, and the last subject was enrolled on 23 JUL 2015. In Substudy 2, the first subject was enrolled on 05 NOV 2014, and the last subject was enrolled on 02 OCT 2015.
| Milestone | Substudy 1: Ruxolitinib + Regorafenib | Substudy 1: Placebo + Regorafenib | Substudy 2: Ruxolitinib + Regorafenib | Substudy 2: Placebo + Regorafenib |
|---|---|---|---|---|
| Started | 87 | 88 | 110 | 111 |
| Treated patients | 85 | 86 | 106 | 106 |
| Completed | 4 | 2 | 13 | 10 |
| Not completed | 83 | 86 | 97 | 101 |
| Withdrew: Adverse event | 9 | 17 | 10 | 10 |
| Withdrew: Disease progression | 53 | 55 | 68 | 73 |
| Withdrew: Patient decision, inc. consent withdrawn | 4 | 5 | 5 | 6 |
| Withdrew: Physician decision | 4 | 2 | 3 | 2 |
| Withdrew: Death | 9 | 3 | 2 | 1 |
| Withdrew: Noncompliance | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 0 |
| Withdrew: Other, unspecified | 2 | 1 | 3 | 4 |
| Withdrew: Did not receive study med | 2 | 2 | 4 | 5 |
Overall survival is defined as the time from randomization to death due to any cause. Participants without death observed at the time of the analysis will be censored at last date known to be alive. The median overall survival time was estimated using the Kaplan-Meier method. Overall survival was compared between treatment groups using log-rank test.
| months | Substudy 1: Ruxolitinib + Regorafenib | Substudy 1: Placebo + Regorafenib | Substudy 2: Ruxolitinib + Regorafenib | Substudy 2: Placebo + Regorafenib |
|---|---|---|---|---|
| Overall Survival (OS) | 4.6 (3.5 to 5.4) | 5.3 (4.3 to 6.0) | 11.4 (9.0 to 13.2) | 10.9 (7.2 to NA) |
Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at least a 20% increase in the sum of the Longest Diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions, or the appearance of new lesions.
| months | Substudy 1: Ruxolitinib + Regorafenib | Substudy 1: Placebo + Regorafenib | Substudy 2: Ruxolitinib + Regorafenib | Substudy 2: Placebo + Regorafenib |
|---|---|---|---|---|
| Progression Free Survival (PFS) | 2.2 (1.9 to 3.0) | 2.1 (1.8 to 2.7) | 3.5 (3.0 to 3.8) | 2.0 (1.9 to 3.1) |
Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target and non-target lesions without new lesion; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions, non-target lesion not progressed, and no new lesion; Progressive Disease=20% increase in sum of longest diameter of target lesions, or non-target lesion progression, or identification of new lesion; Stable Disease=small changes that do not meet above criteria. ORR was defined as the proportion of participants who achieved a best response of either CR or PR. ORR=number of participants with CR or PR/number of participants randomized.
| percentage of responders | Substudy 1: Ruxolitinib + Regorafenib | Substudy 1: Placebo + Regorafenib | Substudy 2: Ruxolitinib + Regorafenib | Substudy 2: Placebo + Regorafenib |
|---|---|---|---|---|
| Overall Response Rate (ORR) | 0.0 (0.0 to 4.2) | 0.0 (0.0 to 4.1) | 2.7 (0.6 to 7.8) | 4.5 (1.5 to 10.2) |
Duration of response is defined as the time from response (CR/PR) until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause.
No measurements were reported for this outcome.
Disease control as measured by the percentage of participants whose best response was complete response (CR), partial response (PR), or stable disease (SD) per RECIST v.1.1.
| percentage of participants | Substudy 1: Ruxolitinib + Regorafenib | Substudy 1: Placebo + Regorafenib | Substudy 2: Ruxolitinib + Regorafenib | Substudy 2: Placebo + Regorafenib |
|---|---|---|---|---|
| Percentage of Participants Achieving Disease Control | 40.2 (29.9 to 51.3) | 34.1 (24.3 to 45.0) | 61.8 (52.1 to 70.9) | 36.9 (28.0 to 46.6) |
TEAEs were defined as any adverse event (AE) during the study that began or worsened on or after the date of first dose of investigational product.
| percentage of participants | Substudy 1: Ruxolitinib + Regorafenib | Substudy 1: Placebo + Regorafenib | Substudy 2: Ruxolitinib + Regorafenib | Substudy 2: Placebo + Regorafenib |
|---|---|---|---|---|
| Participants with any TEAEs | 100.0 | 100.0 | 100.0 | 99.1 |
| Participants with Grade 3/4 TEAEs | 82.4 | 81.4 | 77.4 | 72.6 |
| Participants with any serious TEAE | 57.6 | 48.8 | 34.9 | 34.9 |
| Participants with a fatal TEAE | 15.3 | 9.3 | 1.9 | 3.8 |
| Participants who discontinued drug due to of TEAEs | 14.1 | 19.8 | 11.3 | 10.4 |
Collected over From the first dose of study medication up to 16 months or data cut-off 11 FEB 2016.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Substudy 1: Ruxolitinib + Regorafenib | — | 49/85 (57.6%) | 85/85 (100%) |
| Substudy 1: Placebo + Regorafenib | — | 42/86 (48.8%) | 86/86 (100%) |
| Substudy 2: Ruxolitinib + Regorafenib | — | 37/106 (34.9%) | 106/106 (100%) |
| Substudy 2: Placebo + Regorafenib | — | 37/106 (34.9%) | 105/106 (99.1%) |
| Event | Substudy 1: Ruxolitinib + Regorafenib | Substudy 1: Placebo + Regorafenib | Substudy 2: Ruxolitinib + Regorafenib | Substudy 2: Placebo + Regorafenib |
|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 6/85 | 7/86 | 4/106 | 5/106 |
| SepsisInfections and infestations | 6/85 | 1/86 | 1/106 | 1/106 |
| Hepatobiliary disordersGeneral disorders | 5/85 | 2/86 | 0/106 | 0/106 |
| PneumoniaInfections and infestations | 5/85 | 2/86 | 0/106 | 0/106 |
| Small intestinal obstructionGastrointestinal disorders | 2/85 | 1/86 | 0/106 | 5/106 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/85 | 2/86 | 5/106 | 1/106 |
| General physical health deteriorationGeneral disorders | 4/85 | 3/86 | 1/106 | 1/106 |
| Blood bilirubin increasedInvestigations | 4/85 | 1/86 | 0/106 | 3/106 |
| VomitingGastrointestinal disorders | 2/85 | 4/86 | 3/106 | 4/106 |
| AnaemiaBlood and lymphatic system disorders | 0/85 | 0/86 | 4/106 | 0/106 |
| Event | Substudy 1: Ruxolitinib + Regorafenib | Substudy 1: Placebo + Regorafenib | Substudy 2: Ruxolitinib + Regorafenib | Substudy 2: Placebo + Regorafenib |
|---|---|---|---|---|
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 36/85 | 38/86 | 61/106 | 50/106 |
| FatigueGeneral disorders | 29/85 | 31/86 | 43/106 | 47/106 |
| HypertensionVascular disorders | 18/85 | 22/86 | 44/106 | 42/106 |
| DiarrhoeaGastrointestinal disorders | 32/85 | 27/86 | 41/106 | 29/106 |
| Decreased appetiteMetabolism and nutrition disorders | 31/85 | 31/86 | 28/106 | 35/106 |
| ConstipationGastrointestinal disorders | 27/85 | 21/86 | 24/106 | 22/106 |
| NauseaGastrointestinal disorders | 22/85 | 22/86 | 30/106 | 22/106 |
| Abdominal painGastrointestinal disorders | 21/85 | 24/86 | 24/106 | 26/106 |
| AstheniaGeneral disorders | 22/85 | 22/86 | 19/106 | 23/106 |
| AnaemiaBlood and lymphatic system disorders | 10/85 | 12/86 | 27/106 | 12/106 |
The intent-to-treat (ITT) population consisted of participants that were randomized in the study.
| Age, Continuous(years) | Substudy 1: Ruxolitinib + Regorafenib | Substudy 1: Placebo + Regorafenib | Substudy 2: Ruxolitinib + Regorafenib | Substudy 2: Placebo + Regorafenib | Total |
|---|---|---|---|---|---|
| Mean | 60.8 (34.0 to 84.0) | 59.5 (36.0 to 81.0) | 59.0 (37.0 to 79.0) | 59.2 (19.0 to 83.0) | 59.6 (19 to 84) |
| Sex: Female, Male(Participants) | Substudy 1: Ruxolitinib + Regorafenib | Substudy 1: Placebo + Regorafenib | Substudy 2: Ruxolitinib + Regorafenib | Substudy 2: Placebo + Regorafenib | Total |
|---|---|---|---|---|---|
| Female | 34 | 32 | 48 | 54 | 168 |
| Male | 53 | 56 | 62 | 57 | 228 |
| Race (NIH/OMB)(Participants) | Substudy 1: Ruxolitinib + Regorafenib | Substudy 1: Placebo + Regorafenib | Substudy 2: Ruxolitinib + Regorafenib | Substudy 2: Placebo + Regorafenib | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 2 | 10 | 9 | 21 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 7 | 7 | 6 | 7 | 27 |
| White | 70 | 70 | 84 | 80 | 304 |
| More than one race | 10 | 9 | 5 | 11 | 35 |
| Unknown or Not Reported | 0 | 0 | 4 | 4 | 8 |
The record gives a start of Mar 2014, a primary completion of Feb 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib